Eur J Cancer. 2009 Jan;45(2):225-7. Epub 2008 Dec 8.

Cancer clinical trial outcomes: any progress in tumour-size assessment?

Verweij J, Therasse P, Eisenhauer E; RECIST working group.

Source

Department of Medical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, Rotterdam, The Netherlands. j.verweij@erasmusmc.nl

Abstract

Cancer for many patients is still a lethal disease, and we are at the edge of the time that it will be the leading cause of death in the western world. One of the hallmarks of cancer is its ability to spread to other organs, turning cancer in essence to a systemic disease. For this reason, systemic therapy plays an important role in our efforts to either obtain cure or to prolong life and palliate symptoms. The ultimate goal in the development of such new treatments is cure or prolongation of life, but the process to ascertain this may be lengthy. This presents a limitation to the rapid assessment of the potential benefit of new cancer treatments, which is why investigators and regulators have been interested in clinical trial measures that could provide early readouts of drug activity or efficacy, in other words for surrogate indicators for the ultimately desired outcome.

PMID:: 19068275; [PubMed - indexed for MEDLINE]

MeSH Terms

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Review Do we make optimal use of the potential of cancer prevention? [Recent Results Cancer Res. 2009]
Review Do we make optimal use of the potential of cancer prevention?
Greenwald P, Dunn BK. Recent Results Cancer Res. 2009; 181:3-17.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). [Eur J Cancer. 2009]
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. Eur J Cancer. 2009 Jan; 45(2):228-47.
Review Improving cancer outcomes through international collaboration in academic cancer treatment trials. [J Clin Oncol. 2009]
Review Improving cancer outcomes through international collaboration in academic cancer treatment trials.
Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, et al. J Clin Oncol. 2009 Oct 20; 27(30):5109-14. Epub 2009 Aug 31.
What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century? [Med J Aust. 2009]
What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?
Olver IN, Haines IE. Med J Aust. 2009 Jan 19; 190(2):74-7.
Review Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? [Eur J Cancer. 2009]
Review Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?
Ohorodnyk P, Eisenhauer EA, Booth CM. Eur J Cancer. 2009 Sep; 45(13):2249-52. Epub 2009 Jun 21.

See reviews... See all...

Cited by 5 PubMed Central articles

Preclinical multimodality phantom design for quality assurance of tumor size measurement. [BMC Med Phys. 2011]
Preclinical multimodality phantom design for quality assurance of tumor size measurement.
Lee YC, Fullerton GD, Baiu C, Lescrenier MG, Goins BA. BMC Med Phys. 2011 Sep 30; 11:1. Epub 2011 Sep 30.
Review Predicting and monitoring cancer treatment response with diffusion-weighted MRI. [J Magn Reson Imaging. 2010]
Review Predicting and monitoring cancer treatment response with diffusion-weighted MRI.
Thoeny HC, Ross BD. J Magn Reson Imaging. 2010 Jul; 32(1):2-16.
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. [Br J Cancer. 2010]
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Vroling L, Lind JS, de Haas RR, Verheul HM, van Hinsbergh VW, Broxterman HJ, Smit EF. Br J Cancer. 2010 Jan 19; 102(2):268-75. Epub 2009 Dec 15.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Cancer clinical trial outcomes: any progress in tumour-size assessment?
Cancer clinical trial outcomes: any progress in tumour-size assessment?
Eur J Cancer. 2009 Jan ;45(2):225-7. Epub 2008 Dec 8 .

PubMed
Stable DNA transfection of a wide range of trypanosomatids.
Stable DNA transfection of a wide range of trypanosomatids.
Mol Biochem Parasitol. 1991 May ;46(1):169-79.

PubMed
Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis an...
Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes.
J Cell Physiol. 2009 Apr ;219(1):84-93.

PubMed
Molecular analysis of a human interferon-inducible gene family.
Molecular analysis of a human interferon-inducible gene family.
Eur J Biochem. 1991 Jul 15 ;199(2):417-23.

PubMed
Functionally related transcripts have common RNA motifs for specific RNA-binding...
Functionally related transcripts have common RNA motifs for specific RNA-binding proteins in trypanosomes.
BMC Mol Biol. 2008 Dec 8 ;9:107.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Cancer clinical trial outcomes: any progress in tumour-size assessment?

Source

Abstract

MeSH Terms

MeSH Terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Libraries

Supplemental Content

Save items

Related citations in PubMed

Cited by 5 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information